Novel agents for the treatment of childhood leukemia: an update


Eryilmaz E., Canpolat C.

ONCOTARGETS AND THERAPY, cilt.10, ss.3299-3306, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 10
  • Basım Tarihi: 2017
  • Doi Numarası: 10.2147/ott.s126368
  • Dergi Adı: ONCOTARGETS AND THERAPY
  • Sayfa Sayıları: ss.3299-3306

Özet

Achieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed. This review provides an overview of better practice in the treatment of childhood leukemia.